With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.
Amber Gilbert
Advertisement
Articles by Amber Gilbert
Advertisement
Latest Updated Articles
- Is Pharma Losing the Centerpiece of Its Market Access Toolbox?
Published: December 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline
2
Pediatricians Mostly Side With AAP Over CDC in Vaccine Guidance Debate: Report
3
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
4
Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics
5